Perspective Therapeutics: New name, new headquarters

Precision and personalization are just two of the characteristics that Perspective Therapeutics executives agree make its clinical drugs in development a game changer for cancer patients. 

The company, formerly known as Viewpoint Molecular Targeting, merged with Seattle, Washington-based Isoray Inc. in September and formalized the agreement with the publicly traded company earlier this month. As part of the merger, Viewpoint…